Startup R3 Bio Develops Brainless Organ Systems as Ethical Alternative to Animal Testing and Future Human Organ Source A Bay Area biotech startup called R3 Bio is developing genetically engineered 'organ sacks'—whole organ systems lacking a brain to eliminate sentience and pain perception—as a replacement for animal testing in drug development. Cofounder Alice Gilman explains that these structures would include typical organs but exclude brain development through stem cell technology and gene editing, starting with mouse models and aiming for monkey versions to test drug toxicity more scalably and ethically. The approach addresses shortages of research monkeys in the US, exacerbated by export bans from China, federal phase-outs of animal experimentation under the Trump administration, and ethical concerns from animal rights groups. R3 Bio draws from the 'three Rs' philosophy (replacement, reduction, refinement) in animal research. Beyond testing, the long-term vision includes creating nonsentient human 'organ sacks' or 'bodyoids' to supply tissues, blood, and organs for transplant patients, tackling the severe organ shortage where over 100,000 Americans wait and 13 die daily. Investors include billionaire Tim Draper, LongGame Ventures, and Singapore-based Immortal Dragons longevity fund, which sees organ replacement as superior to repair for treating aging and disease. Experts note plausibility using induced pluripotent stem cells with brain-development genes disabled, but ethical questions remain about creation, storage, and public perception of such entities. While highly theoretical and early-stage (currently working with monkey cells and seeking primate veterinarians), the concept could advance regenerative medicine if successful.

Startup R3 Bio Develops Brainless Organ Systems as Ethical Alternative to Animal Testing and Future Human Organ Source

🤖 IA: It's clickbait ⚠️
👥 Usuarios: It's clickbait ⚠️

#biotech #animaltesting #organreplacement

View full AI summary: